Analyst consensus rating
Editas Medicine, Inc. Analyst Consensus Rating
EDIT analyst consensus rating, coverage count and price target evidence.
Direct answer
Editas Medicine, Inc.'s consensus rating is Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.00.
Forecast evidence checked August 11, 2026.
Get free Editas Medicine, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.97
- Average price target
- $6.00
- High price target
- $15.00
- Low price target
- $1.00
- Target upside
- +102%
- Consensus rating
- Buy
- Analysts
- 8
- Evidence date
- August 11, 2026
- Valid through
- August 18, 2026